RPR's LOVENOX BLEEDING COMPARED WITH COUMADIN IN 74-PATIENT STUDY
Executive Summary
RPR's LOVENOX BLEEDING COMPARED WITH COUMADIN IN 74-PATIENT STUDY conducted to examine cost-effectiveness of the two anticoagulants at an Ohio hospital. The study was presented Dec. 7 at the American Society of Hospital Pharmacists mid-year meeting in Miami Beach. Pharmacist Kelly Konz compared Rhone-Poulenc Rorer's Lovenox (enoxaparin) and DuPont-Merck's Coumadin (warfarin) "in terms of relevant costs from a hospital perspective and outcomes of prophylaxis following hip replacement surgery" for deep vein thrombosis and pulmonary embolism. Konz conducted the study at Grant Medical Center, a 640-bed private teaching hospital.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth